+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.

Age: 50Years +All GendersPhase 3
566 locations
P

Actively Recruiting

Researchers are evaluating the drug PALI-2108 in adults with moderate to severe ulcerative colitis, a condition causing inflammation in the colon. This phase 2 study compares different doses of PALI-2108 against a placebo to assess how well the drug works, its safety, and how the body processes it. The study focuses on measuring clinical remission and endoscopic improvement to understand the drugs impact. Participants will receive either 15 mg or 30 mg of PALI-2108 once daily or a matching placebo. The treatment is given orally, and the study uses a randomized, double-blind design where neither participants nor researchers know which treatment is assigned. The study includes induction and maintenance therapy periods, with assessments at 12 weeks and up to 48 weeks to evaluate clinical response and remission. During the study, participants will undergo regular clinical evaluations including the modified Mayo Score assessments, endoscopic examinations, and monitoring for adverse effects. The primary outcome is the proportion of participants achieving clinical remission at Week 12. Secondary outcomes include clinical response and endoscopic improvements at Weeks 12 and 48. Participants safety and drug effects will be closely monitored throughout the study duration, which may last up to about two years from enrollment.

Age: 18Years - 75YearsAll GendersPhase 2
115 locations
P

Actively Recruiting

Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.

Age: 18Years +All GendersPhase 3
804 locations
P

Actively Recruiting

Researchers are conducting a national, prospective, multicenter, non-interventional pilot project to screen for Hepatitis C virus HCV infection among people who inject drugs PWID in the Czech Republic. The main goal is to prepare, implement, and assess a method for early detection of Hepatitis C and to develop new procedures for integrating this screening into social health care systems. This project aims to help prevent further transmission of the virus by improving early diagnosis and care continuity.

Age: 18Years +All Genders
18 locations
N

Actively Recruiting

Researchers are investigating invasive pulmonary aspergillosis IPA, a serious lung infection mostly caused by Aspergillus fumigatus, which has increased significantly in critically ill patients, especially those with severe respiratory infections like COVID-19 and H1N1. Current biomarkers only suggest probable IPA, so this study aims to evaluate new low molecular weight substances combined with acute-phase proteins to confirm IPA quickly and accurately. The goal is to improve early diagnosis and treatment outcomes in intensive care patients. This study collects multiple types of samples such as tissue, bronchoalveolar lavage fluid, endotracheal aspirate, breath condensate, serum, and urine from patients suspected of IPA. Using advanced mass spectrometry techniques including MALDI-TOF, researchers will detect specific microbial markers alongside host proteins to confirm infection. Samples will be taken twice weekly until negative results or discharge, and stored samples from before diagnosis may also be analyzed. The study compares groups of patients with suspected IPA and those with probable or proven IPA. Participants will undergo regular testing including imaging, mycological cultures, PCR tests, and biomarker analyses. Data on clinical history, treatment, and biological markers will be collected and analyzed statistically to evaluate the diagnostic accuracy of the new methods. Results will be reported to clinicians in variable timeframes. The primary outcome is the concentration of IPA markers detected by mass spectrometry over 31 months. The study runs until the end of 2026 and involves critically ill adult patients in intensive care units.

Age: 18Years +All Genders
7 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
E

Actively Recruiting

The study focuses on patients with various conditions related to plasma cells, including Monoclonal Gammopathy of Undetermined Significance MGUS, smoldering Multiple Myeloma SMM, Multiple Myeloma MM, and Plasma Cell Leukemia PCL. It is an observational, non-interventional, multicenter research project aimed at collecting, storing, and analyzing biological samples from these patients. The purpose is to create an international infrastructure for gathering consistent clinical data and biological samples at different stages of disease and treatment. Participants provide biological samples such as bone marrow aspirate, bone marrow biopsy, extramedullary disease EMD biopsy, peripheral blood, and serum at multiple timepoints. These include baseline, pre-maintenance or after one year of therapy depending on transplant eligibility, during maintenance therapy if part of standard care, and at first or later progression of disease. The study collects and stores these samples over a long period to support future research. Participants will undergo sample collections at scheduled times during their disease course and treatment phases. Researchers will monitor and analyze the stored biological samples and clinical data to support a biobank lasting up to 30 years. The study does not involve any experimental treatments but focuses on gathering data and samples to better understand the conditions. Participation requires written informed consent and compliance with the protocols follow-up schedule.

Age: 18Years +All Genders
41 locations
E

Actively Recruiting

Researchers are evaluating maridebart cafraglutide as an additional treatment to standard care to reduce heart failure events, cardiovascular deaths, and improve symptoms in adults with heart failure who have preserved or mildly reduced ejection fraction and obesity. This phase 3 global trial includes a double-blind period followed by an open-label extension. The study will continue until approximately 850 primary endpoint events have occurred, focusing on serious heart failure outcomes. Participants will be randomly assigned to receive either maridebart cafraglutide or a placebo, both given by subcutaneous injection. The trial includes two parts an initial double-blind phase where neither participants nor researchers know the assigned treatment, followed by an open-label extension where all participants may receive the active drug. This design helps assess the drugs impact on heart failure and related cardiovascular events. During the study, participants will undergo regular assessments including questionnaires to measure heart failure symptoms and quality of life, blood tests for kidney function, blood sugar, cholesterol, and inflammation markers, as well as monitoring of heart failure events and mortality. The main outcome is the time until cardiovascular death or heart failure events over about 35 months. Safety and other health measures will also be tracked throughout the trial, which lasts up to about three years.

Age: 18Years - 99YearsAll GendersPhase 3
686 locations